For many years, Alzheimer’s disease was usually diagnosed only after memory loss became serious. Families often spent years searching for answers while patients slowly lost their ability to think clearly, remember daily events, or recognize loved ones.
Doctors mainly depended on brain scans and spinal fluid testing to confirm Alzheimer’s disease. These methods were accurate but expensive, time-consuming, and uncomfortable for patients.
Today, the situation is changing quickly.
Several biotechnology and diagnostic companies are developing blood-based biomarker tests that can detect Alzheimer’s disease much earlier. These tests look for specific proteins in the blood linked to brain changes caused by Alzheimer’s. A simple blood sample may soon help doctors identify the disease years before major symptoms appear.
As the number of Alzheimer’s patients continues to grow worldwide, these companies are becoming some of the most important players in healthcare and neuroscience.
Alzheimer’s Cases Are Rising Rapidly
Alzheimer’s disease is the most common form of dementia, responsible for nearly 60% to 70% of dementia cases globally. More than 55 million people worldwide currently live with dementia, and the number continues to increase as populations age.
In the United States alone, nearly 7 million people are living with Alzheimer’s disease. Experts expect that number to rise sharply over the next two decades.
The growing patient population has created a huge demand for faster and more affordable diagnostic tools. This is where biomarker companies are making a major impact.
What Are Alzheimer’s Biomarkers?
Biomarkers are measurable biological signals found in blood, spinal fluid, or brain tissue. In Alzheimer’s disease, scientists focus heavily on proteins linked to brain cell damage and plaque buildup.
Some of the most important biomarkers include:
- pTau217
- pTau181
- Amyloid beta 42/40
- GFAP
- Neurofilament light chain (NfL)
These biomarkers help doctors estimate whether Alzheimer’s-related changes are happening inside the brain, even before severe memory problems begin.
Leading Companies in Alzheimer’s Disease Biomarkers
| Company | Main Focus Area | Key Strength |
|---|---|---|
| Fujirebio | Blood biomarker testing | FDA-cleared Alzheimer’s blood test |
| Roche | Diagnostic systems | Large global laboratory network |
| Quanterix | Ultra-sensitive detection technology | High-precision biomarker analysis |
| C2N Diagnostics | Blood-based Alzheimer’s testing | Strong clinical performance |
| Labcorp | Clinical testing services | Nationwide diagnostic access |
| Quest Diagnostics | Alzheimer’s screening services | Large-scale healthcare reach |
| Siemens Healthineers | Automated diagnostics | Advanced testing platforms |
| Abbott | Neuro biomarker development | Global diagnostics ecosystem |
Fujirebio Became a Major Industry Leader
Fujirebio gained global attention after developing one of the first FDA-cleared blood tests for Alzheimer’s disease.
Its test measures proteins such as pTau217 and beta-amyloid levels in the blood. Instead of relying on brain scans or spinal fluid collection, doctors can now use a simple blood sample to help identify Alzheimer’s-related brain changes.
This was considered a major breakthrough because blood testing is easier, faster, and more accessible for patients.
The company’s success also pushed many competitors to accelerate their own biomarker programs.
Roche Is Expanding Alzheimer’s Testing Worldwide
Roche is one of the world’s largest diagnostic companies, and it is heavily investing in Alzheimer’s biomarker testing.
The company is integrating Alzheimer’s biomarker analysis into its existing diagnostic systems already used in thousands of laboratories worldwide. This gives Roche a major advantage because hospitals and clinics can adopt testing more quickly without installing completely new systems.
Roche is also working closely with pharmaceutical companies developing Alzheimer’s drugs. Many newer treatments require confirmation of amyloid plaque buildup before patients can begin therapy.
As demand for treatment grows, demand for reliable biomarker testing is growing alongside it.
Quanterix Built Extremely Sensitive Detection Technology
Quanterix became well known for its Simoa technology platform, designed to detect extremely tiny amounts of biomarkers in blood samples.
This level of sensitivity is important because Alzheimer’s-related proteins often appear in very small concentrations during the early stages of disease.
Many researchers, hospitals, and pharmaceutical companies now use Quanterix technology in clinical trials and neuroscience research programs.
Its systems are helping scientists study Alzheimer’s progression with greater accuracy than before.
C2N Diagnostics Is Gaining Strong Clinical Recognition
C2N Diagnostics has become one of the most respected companies in Alzheimer’s blood testing.
Its PrecivityAD blood test is widely discussed in neurological research because of its strong performance in identifying Alzheimer’s-related pathology.
The company combines biomarker analysis with advanced algorithms to estimate the likelihood of Alzheimer’s disease in patients experiencing memory problems.
Many specialists believe this approach could improve early diagnosis and help doctors decide which patients may benefit from newer Alzheimer’s therapies.
Why Biomarker Companies Matter More Than Ever
The rise of Alzheimer’s biomarker companies is closely connected to the development of new Alzheimer’s drugs.
Modern therapies are increasingly focused on slowing disease progression during earlier stages rather than treating severe late-stage symptoms. Early diagnosis therefore becomes extremely important.
Without fast and scalable testing methods, millions of patients may struggle to access appropriate treatment at the right time.
That is why blood biomarker testing is now considered one of the most important developments in modern neuroscience.
The Future of Alzheimer’s Detection
Researchers believe Alzheimer’s testing may soon become part of routine healthcare checkups.
Future technologies may include AI-powered diagnostics, wearable monitoring devices, and portable biomarker testing systems that can identify brain changes even earlier.
The goal is no longer just diagnosing Alzheimer’s disease after symptoms appear. The real focus is finding the disease early enough to slow progression and improve quality of life.
For millions of families worldwide, these companies are not only developing diagnostic tools — they are helping create hope for earlier answers and better treatment options.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium